

Cotempla XR-ODT - (8.6, 17.3, 25.9 mg; Tablet, Extended-release, Orally Disintegrating)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Methylphenidate | Innovator | Neos Therapeutics |
| Dosage | 8.6, 17.3, 25.9 mg; Tablet, Extended-release, Orally Disintegrating | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | COTEMPLA XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.